HIV treatment Biktarvy is aiming to expand pediatric indications in Korea. According to related industries, Gilead Science Korea recently submitted an application to expand indications for pediatric patients who weigh at least 14kg to 25kg of the HIV compound Biktarvy and have no experience in antiretroviral treatment or have been suppressed by existing antiretroviral treatment.

The efficacy of Biktarvy in pediatric patients was confirmed through data from cohort 3 of clinical trials in a single clinical trial with phase 2/3 open markers. In the study, Biktarvy low-dose tablets were found to be generally drug-resistant and effective for 24 weeks in HIV-1-infected children with suppressed virus levels. C